The anti-inflammatory biological therapy canakinumab (Ilaris) has been found to more than halve the rate of gout in atherosclerosis patients. In a secondary analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which examined the effectiveness of the canakinumab for the prevention of cardiovascular events, the effect on gout was seen regardless of ...
Gout attacks halved in atherosclerosis patients treated with canakinumab
By Ingrid Torjesen
25 Jun 2018